Juno Therapeutics Inc (JUNO)

30.37
NASDAQ : Health Care
Prev Close 30.37
Day Low/High 0.00 / 0.00
52 Wk Low/High 22.37 / 57.82
Avg Volume 2.06M
Exchange NASDAQ
Shares Outstanding 105.54M
Market Cap 3.22B
EPS -2.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

INVESTOR ALERT: Brower Piven Notifies Shareholders Of Securities Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Juno Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Western District of Washington on behalf...

'Mad Money' Lightning Round: Take Bristol-Myers Over Juno

Cramer says Abiomed is too expensive while Harman was hurt by the strong dollar.

Jim Cramer's 'Mad Money' Recap: Why Some Stocks Pass Earnings Test and Others Fail

Johnson & Johnson was easy, Cramer says, but other stocks were more problematic.

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

Celgene continues to sprinkle cash around the biotech sector, tying up with smaller companies for first-dibs access to potentially valuable drugs and technologies.

Robbins Arroyo LLP: Juno Therapeutics, Inc. (JUNO) Misled Shareholders According To A Recently Filed Class Action

Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Juno Therapeutics, Inc.

Juno Therapeutics Adds Adenosine Receptor Antagonist Through Acquisition Of RedoxTherapies

Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, announced today that it has acquired RedoxTherapies, Inc.

Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of Juno Therapeutics, Inc. Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray LLP ("GPM") announces that a class action lawsuit has been filed on behalf of investors who purchased Juno Therapeutics, Inc.

S&P 500, Dow Barely Beat Records in Little-Changed Session

Crude oil kept markets under pressure on Wednesday after erasing big gains achieved over the previous session.

6 Big Stocks to Add to Your Buy List -- Plus 1 to Avoid

Here's a technical look at how to trade some of the most active stocks on the market right now.

Stocks Mixed After Fed's Beige Book Reports 'Modest' Growth in U.S.

Stocks are mixed Wednesday after the latest reading on the U.S. economy shows a steady state of growth.

Stocks Struggle for Direction as Crude Extends Decline

Stocks struggle to determine direction on Wednesday as Wall Street takes a slight pause after two days of record-making runs.

Juno Therapeutics (JUNO) Stock Surges After FDA Lifts Clinical Hold

Juno Therapeutics (JUNO) stock is surging in early-morning trading as a result of the FDA lifting the clinical hold placed on 'its lead pivotal trial' that resulted in two deaths.

Juno Therapeutics to Resume Drug Study

Juno Therapeutics shares are soaring following news that a study of an experimental treatment for leukemia has been allowed to resume.

Stock Futures on Pause After Wall Street's Record-Making Run

Stock futures make smaller moves higher on Wednesday as Wall Street takes a pause after two days of record-making runs.

Morning Movers: JUNO, AMZN, VRX, MIK

Juno Therapeutics allowed to resume drug trial while Valeant's largest shareholder exits.

U.S. Stocks Pause After Record Run, Transports Move Out of Correction

U.S. Stocks are taking a breather after hitting fresh record highs this week.

July 13 Premarket Briefing: 10 Things You Should Know

U.S. stock futures are rising slightly Wednesday following Tuesday's action that saw U.S. benchmarks finish at record highs.

Futures Rein In After Records Set; Asia Steps Up

Maybe investors aren't so gung-ho after three days of gains and record closes.

Juno Shares Jump in After-Hours Trading as FDA Removes Clinical Hold on JCAR015 Phase 2 Trial

Five days after the federal agency had halted the clinical trial, the Seattle biopharma company said it will testing the leukemia drug candidate.

Juno Therapeutics To Resume JCAR015 Phase II ROCKET Trial

Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today announced that the U.

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into Juno Therapeutics Inc. For Possible Securities Law Violations And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible securities law violations by certain officers and directors of Juno Therapeutics Inc.